Adalimumab 80mg/0.8ml solution for injection pre-filled disposable devices
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Adalimumab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Adalimumab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
MHRA licensed products
View all licensed products for Adalimumab on the MHRA register
Amgevita HCF 80mg/0.8ml solution for injection pre-filled pens
Humira 80mg/0.8ml solution for injection pre-filled pens
Yuflyma 80mg/0.8ml solution for injection pre-filled pens
WHO defined daily dose (DDD)
2.9 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(15)
Adalimumab for treating moderate to severe plaque psoriasis (TA146)
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (TA715)
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)
Crohn's disease: management (NG129)
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Golimumab for treating active non-radiographic axial spondyloarthritis (TA497)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 9 · Randomised trials: 33 · 2004–2026
Showing the 50 most relevant studies, sorted by most relevant.
Vincent Billioud, William J. Sandborn, Laurent Peyrin‐Biroulet
The American Journal of Gastroenterology, 2011
- Adalimumab
- Infliximab
- Anti-Inflammatory Agents
Y-F Chen, Paresh Jobanputra, Pelham Barton, et al.
Health Technology Assessment, 2006
- Etanercept
- Adalimumab
- Infliximab
C McLeod, A Bagust, Angela Boland, et al.
Health Technology Assessment, 2007
- Cost-Benefit Analysis
- Etanercept
- Adalimumab
Roy Fleischmann, Aileen L. Pangan, In‐Ho Song, et al.
Arthritis & Rheumatology, 2019
- Adalimumab
- Janus Kinase Inhibitors
- Arthritis, Rheumatoid
Kristian Reich, Melinda Gooderham, Diamant Thaçi, et al.
The Lancet, 2019
- Adalimumab
- Antibodies, Monoclonal
- Injections, Subcutaneous
Iain B. McInnes, Frank Behrens, Philip J. Mease, et al.
The Lancet, 2020
- Clinical Decision-Making
- Adalimumab
- Injections, Subcutaneous
Bruce E. Sands, Peter M. Irving, Timothy Hoops, et al.
The Lancet, 2022
- Biological Products
- Crohn Disease
- Adalimumab
Bernard Combe, Alan Kivitz, Yoshiya Tanaka, et al.
Annals of the Rheumatic Diseases, 2021
- Adalimumab
- Arthritis, Rheumatoid
- Methotrexate
Philip J. Mease, Désirée van der Heijde, Christopher T Ritchlin, et al.
Annals of the Rheumatic Diseases, 2016
- Adalimumab
- Arthritis, Psoriatic
- Antirheumatic Agents
Quan Dong Nguyen, Pauline T. Merrill, Glenn J. Jaffe, et al.
The Lancet, 2016
- Adalimumab
- Acute Disease
- Adrenal Cortex Hormones
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
10 to 20 days
Mechanism
Adalimumab binds with specificity to tumor necrosis factor-alpha (TNF-alpha) and…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
1.6 μg/mL
Half-life
2 weeks
[L35370]
Volume of distribution
4.7 to 6.0 L
Elimination
[A40006]
Clearance
0.25 to 10 mg/k
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Several biosimilars to adalimumab. Adalimumab-atto was the first adalimumab biosimilar approved by the FDA in 2016.[L44953] Adalimumab-adaz was approved by the FDA on October 31, 2018.[L4799] Other biosimilars include adalimumab-fkjp - which was approved in July 2022 -,[L42495] adalimumab-bwwd - which was approved in August 2022 -,[L42935], adalimumab-aacf - which was approved in October 2023 [L49101] and adalimumab-ryvk - which was approved in February 2024[L52088]. A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available.[L45643][L45818]. A high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), a biosimilar to Humira®, was approved by the FDA in May 2024 for the treatment of multiple chronic inflammatory diseases.[L53083]
- Moderately to severely active Rheumatoid Arthritis (RA) in adults, as monotherapy or in combination with [methotrexate] or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
[L42290][L42495][L42935][L44953][L45643][L45818][L49101]
- Moderately to severely active polyarticular Juvenile Idiopathic Arthritis (JIA) in patients two years of age and older, as monotherapy or in combination with [methotrexate].
[L42290][L42495][L42935][L44953][L45643][L45818][L49101]
- Psoriatic Arthritis (PsA) in adults.
[L42290][L42495][L42935][L44953][L45643][L45818][L49101]
- Ankylosing Spondylitis (AS) in adults.
[L42290][L42495][L42935][L44953][L45643][L45818][L49101]
- Moderately to severely active Crohn’s Disease (CD) in adults and pediatric patients six years of age and older.
[L42290][L42495][L42935][L44953][L45643][L45818][L49101]
- Moderately to severely active Ulcerative Colitis (UC) in adults. Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
[L42290][L42495][L42935][L44953][L45643][L45818][L49101]
- Moderate to severe chronic plaque psoriasis in adult candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate.
[L42290][L42495][L42935][L44953][L45643][L45818][L49101]
- Moderate to severe Hidradenitis Suppurativa (HS) in adults.
[L44953]
- Non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients two years of age and older.
[L35370]
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
[A40001][A40002]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1361 interactions
[L42290]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L35370]
[L35370]
[L35370]
[A40006]
[L35370]
Proteins and enzymes this drug interacts with in the body
Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective .
PMID:23396208
Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line .
PMID:16829952 PMID:22517918 PMID:23396208
Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance (By similarity).
Plays a role in angiogenesis by inducing VEGF production synergistically with IL1B and IL6 .
PMID:12794819
Promotes osteoclastogenesis and therefore mediates bone resorption (By similarity)
ATC L04AB04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Adalimumab
Additional database identifiers
Drugs Product Database (DPD)
13356
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11892
GenAtlas
TNF
GeneCards
TNF
GenBank Gene Database
M16441
GenBank Protein Database
339741
UniProt Accession
TNFA_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q348260), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.